The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. Export

@article{citeulike:3519701, abstract = {The Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT), a multicenter, randomized, double-blind study, tested the efficacy of cholesterol lowering in reducing risk of coronary heart disease (CHD) in 3,806 asymptomatic middle-aged men with primary hypercholesterolemia (type II hyperlipoproteinemia). The treatment group received the bile acid sequestrant cholestyramine resin and the control group received a placebo for an average of 7.4 years. Both groups followed a moderate cholesterol-lowering diet. The cholestyramine group experienced average plasma total and low-density lipoprotein cholesterol (LDL-C) reductions of 13.4\% and 20.3\%, respectively, which were 8.5\% and 12.6\% greater reductions than those obtained in the placebo group. The cholestyramine group experienced a 19\% reduction in risk (p less than .05) of the primary end point--definite CHD death and/or definite nonfatal myocardial infarction--reflecting a 24\% reduction in definite CHD death and a 19\% reduction in nonfatal myocardial infarction. The cumulative seven-year incidence of the primary end point was 7\% in the cholestyramine group v 8.6\% in the placebo group. In addition, the incidence rates for new positive exercise tests, angina, and coronary bypass surgery were reduced by 25\%, 20\%, and 21\%, respectively, in the cholestyramine group. The risk of death from all causes was only slightly and not significantly reduced in the cholestyramine group. The magnitude of this decrease (7\%) was less than for CHD end points because of a greater number of violent and accidental deaths in the cholestyramine group. The LRC-CPPT findings show that reducing total cholesterol by lowering LDL-C levels can diminish the incidence of CHD morbidity and mortality in men at high risk for CHD because of raised LDL-C levels. This clinical trial provides strong evidence for a causal role for these lipids in the pathogenesis of CHD.}, citeulike-article-id = {3519701}, citeulike-linkout-0 = {http://view.ncbi.nlm.nih.gov/pubmed/6361299}, citeulike-linkout-1 = {http://www.hubmed.org/display.cgi?uids=6361299}, day = {20}, issn = {0098-7484}, journal = {JAMA : the journal of the American Medical Association}, keywords = {cholestyramine, lipids, lrc-cppt}, month = {January}, number = {3}, pages = {351--364}, posted-at = {2008-11-15 23:30:03}, priority = {3}, title = {The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/6361299}, volume = {251}, year = {1984} }

TY - JOUR ID - citeulike:3519701 L3 - citeulike-article-id:3519701 N2 - The Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT), a multicenter, randomized, double-blind study, tested the efficacy of cholesterol lowering in reducing risk of coronary heart disease (CHD) in 3,806 asymptomatic middle-aged men with primary hypercholesterolemia (type II hyperlipoproteinemia). The treatment group received the bile acid sequestrant cholestyramine resin and the control group received a placebo for an average of 7.4 years. Both groups followed a moderate cholesterol-lowering diet. The cholestyramine group experienced average plasma total and low-density lipoprotein cholesterol (LDL-C) reductions of 13.4% and 20.3%, respectively, which were 8.5% and 12.6% greater reductions than those obtained in the placebo group. The cholestyramine group experienced a 19% reduction in risk (p less than .05) of the primary end point--definite CHD death and/or definite nonfatal myocardial infarction--reflecting a 24% reduction in definite CHD death and a 19% reduction in nonfatal myocardial infarction. The cumulative seven-year incidence of the primary end point was 7% in the cholestyramine group v 8.6% in the placebo group. In addition, the incidence rates for new positive exercise tests, angina, and coronary bypass surgery were reduced by 25%, 20%, and 21%, respectively, in the cholestyramine group. The risk of death from all causes was only slightly and not significantly reduced in the cholestyramine group. The magnitude of this decrease (7%) was less than for CHD end points because of a greater number of violent and accidental deaths in the cholestyramine group. The LRC-CPPT findings show that reducing total cholesterol by lowering LDL-C levels can diminish the incidence of CHD morbidity and mortality in men at high risk for CHD because of raised LDL-C levels. This clinical trial provides strong evidence for a causal role for these lipids in the pathogenesis of CHD. IS - 3 JF - JAMA : the journal of the American Medical Association SN - 0098-7484 EP - 364 TI - The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. VL - 251 SP - 351 KW - cholestyramine KW - lipids KW - lrc-cppt PY - 1984/01/20/ UR - http://view.ncbi.nlm.nih.gov/pubmed/6361299 ER -